AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura

Blood

Volumn 121, Issue 19, 2013, Pages 3825-3829

  Jin, Sheng Yu ^a,c   Xiao, Juan ^a,d   Bao, Jialing ^a   Zhou, Shangzhen ^a   Wright, J Fraser ^a,b   Zheng, X Long ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c YANBIAN UNIVERSITY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; ALANINE AMINOTRANSFERASE; RECOMBINANT PROTEIN; SHIGA TOXIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAMTS13 PROTEIN, MOUSE; METALLOPROTEINASE; VEROTOXIN 2;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SMEAR; CELL SURFACE; CONTROLLED STUDY; ENDOTHELIUM CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; STABLE EXPRESSION; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; ULTRAVIOLET SPECTROPHOTOMETRY; VIRAL GENE THERAPY; ADENO ASSOCIATED VIRUS; ANIMAL; CELL PROTECTION; CHEMICALLY INDUCED DISORDER; GENE THERAPY; GENE VECTOR; GENETIC TRANSFORMATION; GENETICS; METHODOLOGY; MOUSE; MOUSE MUTANT; PHYSIOLOGY; STOP CODON;

ANIMALS; CODON, NONSENSE; CYTOPROTECTION; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; METALLOENDOPEPTIDASES; MICE; MICE, KNOCKOUT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SHIGA TOXIN 2; TRANSFORMATION, GENETIC;

MLCS; MLOWN;

EID: 84880468014     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-486779     Document Type: Article

References (24)

1. Sadler JE. A new name in thrombosis, ADAMTS13. Proc Natl Acad Sci USA. 2002; 99(18):11552-11554.
2. Zheng XL, Sadler JE. Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol. 2008;3: 249-277.
3. Amorosi EL, Ultmann JE. Thrombocytopic purpura: report of 16 cases and review of the literature. Medicine (Baltimore). 1966;45:139-159.
4. Rock GA, Shumak KH, Buskard NA, et al; Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325(6):393-397.
5. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488-494.
6. Kokame K, Matsumoto M, Soejima K, et al. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA. 2002;99(18):11902-11907.
7. Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol. 2001;14(2):437-454.
8. Howard MA, Williams LA, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion. 2006; 46(1):154-156.
9. Niiya M, Endo M, Shang D, et al. Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes. Mol Ther. 2009;17(1):34-41.
10. Trionfini P, Tomasoni S, Galbusera M, et al. Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice. Gene Ther. 2009; 16(11):1373-1379.
11. Laje P, Shang D, Cao W, et al. Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy. Blood. 2009;113(10):2172-2180.
12. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med. 2008; 358(21):2240-2248.
13. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357-2365.
14. Ayuso E, Mingozzi F, Montane J, et al. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther. 2010;17(4):503-510.
15. Sommer JM, Smith PH, Parthasarathy S, et al. Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol Ther. 2003;7(1):122-128.
16. Xiao J, Jin SY, Xue J, Sorvillo N, Voorberg J, Zheng XL. Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis. Arterioscler Thromb Vasc Biol. 2011;31(10):2261-2269.
17. Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005;115(10):2752-2761.
18. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med. 2003;127(7):834-839.
19. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther. 2000; 1(2):154-158.
20. Niemeyer GP, Herzog RW, Mount J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood. 2009;113(4): 797-806.
21. Chauhan AK, Motto DG, Lamb CB, et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006;203(3):767-776.
22. De Maeyer B, De Meyer SF, Feys HB, Pareyn I, Vandeputte N, Deckmyn H, et al. The distal carboxyterminal domains of murine ADAMTS13 influence proteolysis of platelet-decorated VWF strings in vivo. J Thromb Haemost. 2010;8(10): 2305-2312.
23. Banno F, Kokame K, Okuda T, et al. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood. 2006;107(8): 3161-3166.
24. Banno F, Chauhan AK, Kokame K, Yang J, Miyata S, Wagner DD, et al. The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. Blood. 2009;113(21): 5323-5329.